Home › Funds › ADAMS STREET PARTNERS LLC › CRVS
ADAMS STREET PARTNERS LLC position in CRVS
CORVUS PHARMACEUTICALS I · Health Care
ADAMS STREET PARTNERS LLC reported holding 3,275,616 shares of CRVS (CORVUS PHARMACEUTICALS I) in its Q2 2026 13F filing — a position valued at US$48.9M, representing 11.06% of its reported portfolio and ranking #4 among its reported holdings. ADAMS STREET PARTNERS LLC has disclosed CRVS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ADAMS STREET PARTNERS LLC's CRVS position evolved
ADAMS STREET PARTNERS LLC first disclosed a stake in CRVS in Q3 2023 at 3,275,616 shares (US$4.8M). The position peaked in Q2 2026 at 3,275,616 shares, worth US$48.9M. Across 12 filings, ADAMS STREET PARTNERS LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 3,275,616 shares valued at US$48.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.28M | $4.78M | New |
| Q4 2023 | 3.28M | $5.77M | Hold |
| Q1 2024 | 3.28M | $5.83M | Hold |
| Q2 2024 | 3.28M | $5.96M | Hold |
| Q3 2024 | 3.28M | $17.30M | Hold |
| Q4 2024 | 3.28M | $17.52M | Hold |
| Q1 2025 | 3.28M | $10.42M | Hold |
| Q2 2025 | 3.28M | $13.10M | Hold |
| Q3 2025 | 3.28M | $24.14M | Hold |
| Q4 2025 | 3.28M | $25.22M | Hold |
| Q1 2026 | 3.28M | $47.92M | Hold |
| Q2 2026 | 3.28M | $48.94M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRVS and 13F data
CRVS (CORVUS PHARMACEUTICALS I) is a Health Care company. 72 other funds we track also report a position in CRVS — the largest reported positions include ORBIMED ADVISORS LLC (US$107.0M), Vivo Capital, LLC (US$41.9M), PERCEPTIVE ADVISORS LLC (US$39.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRVS
- ORBIMED ADVISORS LLC 7.17M sh · $107.05M · Q2 2026
- Vivo Capital, LLC 2.81M sh · $41.92M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.67M sh · $39.85M · Q2 2026
- Deep Track Capital, LP 2.49M sh · $37.23M · Q2 2026
- BRAIDWELL LP 2.13M sh · $31.77M · Q2 2026
- Foresite Capital Management VI LLC 1.83M sh · $27.36M · Q2 2026
- Boxer Capital Management, LLC 1.10M sh · $16.43M · Q2 2026
- Catalio Capital Management, LP 1.08M sh · $16.15M · Q2 2026
- Eversept Partners, LP 747.99K sh · $11.18M · Q2 2026
- DCF Advisers, LLC 637.50K sh · $9.52M · Q2 2026
- Blue Owl Capital Holdings LP 608.60K sh · $9.09M · Q2 2026
- Nextech Invest Ltd. 450.00K sh · $6.72M · Q2 2026
More on ADAMS STREET PARTNERS LLC
FAQ
How long has ADAMS STREET PARTNERS LLC held CRVS?
ADAMS STREET PARTNERS LLC has disclosed CRVS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ADAMS STREET PARTNERS LLC's current position in CRVS?
As of Q2 2026, ADAMS STREET PARTNERS LLC holds 3.28M shares of CRVS (CORVUS PHARMACEUTICALS I), valued at $48.94M, representing 11.06% of its reported portfolio and ranking #4.
Has ADAMS STREET PARTNERS LLC been buying or selling CRVS?
In the latest 13F filing (Q2 2026), ADAMS STREET PARTNERS LLC held unchanged its position in CRVS. The position peaked in Q2 2026 at 3.28M shares.
Which other funds hold CRVS?
Other major institutional holders of CRVS include ORBIMED ADVISORS LLC, Vivo Capital, LLC, PERCEPTIVE ADVISORS LLC, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.